SB109 HFLR Page 1
BOLD FACE denotes Committee Amendments. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
HOUSE OF REPRESENTATIVES - FLOOR VERSION
STATE OF OKLAHOMA
1st Session of the 60th Legislature (2025)
ENGROSSED SENATE
BILL NO. 109 By: Stanley, Hicks, and Nice of
the Senate
and
Miller, Roe, Townley, West
(Tammy), Hefner, Ranson,
Provenzano, Munson, and
Schreiber of the House
[ health insurance - coverage of genetic testing and
cancer imaging - terms – exclusions – codification
- effective date ]
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 6060.5b of Title 36, unless
there is created a duplication in numbering, reads as follows:
A. For the purposes of this section:
1. “Clinical utility” means clinical utility as de fined
pursuant to Section 6060.5a of Title 36 of the Oklahoma Statutes;
2. “Evidence-based cancer imaging ” means appropriate
preventative screening and imaging supported by evidence;
SB109 HFLR Page 2
BOLD FACE denotes Committee Amendments. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
3. “Genetic testing for an inherited mutation ” means multi-gene
testing for an inherited mutation associated with an increased risk
of cancer;
4. “Health benefit plan” means a health benefit plan as defined
pursuant to Section 6060.4 of Title 36 of the Oklahoma Statutes; and
5. “Health care provider ” means any physician, ho spital, or
other entity or person that is licensed or otherwise authorized in
this state to furnish health care services.
B. Any health benefit plan including the Oklahoma Employees
Insurance Plan that is offered, issued, or renewed in this state on
or after the effective date of this act shall provide coverage for:
1. Clinical genetic testing for an inherited gene mutation for
individuals with a personal or family history of cancer when such
test provides clinical utility and when ordered or recommended by a
health care provider in accordance with medical and scientific
evidence including, but not limited to:
a. the most recent version of the National Comprehensive
Cancer Network (NCCN) clinical practice
recommendations that are Category 2A or higher,
b. Centers for Medicare and Medicaid Services national
coverage determinations or Medicare administrative
contractor local coverage determinations, or
c. nationally recognized clinical practice guidelines;
and
SB109 HFLR Page 3
BOLD FACE denotes Committee Amendments. 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. Evidence-based cancer imaging for individuals with an
increased risk of cancer when such test provides clinical utility
and when ordered or recommended by a health care provider in
accordance with the most recent version of the NCCN clinical
practice recommendations that are Category 2A or higher, or in
accordance with other nationally recognized clinical practice
guidelines.
C. Coverage under this section shall not be subject to any
annual deductibles, copayments, or coinsurance limits as established
for all covered benefits under the health benefit plan.
D. If application of this section would result in health
savings account ineligibility under Section 223 of the Internal
Revenue Code of 1986, as amended, the provisions of this section
shall only apply to health savings accounts with qualified hig h
deductible health plans with respect to the deductible of such a
plan after the enrollee has satisfied the minimum deductible.
Provided, however, the provisions of this section shall apply to
items or services that are preventive care pursuant to Sectio n
223(c)(2)(C) of the Internal Revenue Code of 1986, as amended,
regardless of whether the minimum deductible has been satisfied.
SECTION 2. This act shall become effective November 1, 2025.
COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS AND BUDGET, dated
04/16/2025 - DO PASS, As Amended and Coauthored.